Patients will be able to receive the immunotherapy in a vaccine, called nivolumab, in a treatment that will take just 15 minutes rather than spending an hour on an IV drip.
Around 1,200 patients a month will receive it for 15 different types of cancer, including skin, bladder and oesophageal cancer as England becomes the first country in Europe to offer it.
The drug is a monoclonal antibody that works by clinging to a protein called PD-1 on an immune cell called T-cell. It works by blocking cancer cells from switching off T-cells, allowing the immune system to seek out and destroy cancer cells.
